Navigation Links
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
Date:12/4/2008

es showed highly statistically significant results in the proportion of subjects with no photophobia (light sensitivity) at every study visit post-cataract surgery. This is in concordance with previous clinical trials with Xibrom. The studies also showed no serious ocular or systemic adverse events, and the safety profile is consistent with ISTA's currently marketed Xibrom twice-daily formulation.

ISTA has discussed the data with the FDA and plans to perform a confirmatory Phase III trial that it expects to complete in 2009.

Study Design

According to the Phase III protocols, patients who were undergoing cataract surgery in one eye were assigned randomly (1:1) to receive either Xibrom once daily or placebo. Dosing began one day before cataract surgery and continued for 14 days following surgery. The proportion of patients experiencing no pain was assessed at Day 1 post surgery, and the proportion of patients with complete absence of ocular inflammation was assessed on Day 15 post surgery. Ocular inflammation was evaluated using a summed ocular inflammation score (SOIS) and was measured by an assessment of immune cells in the anterior chamber of the eye ("cells") and cellular debris ("flare"). The secondary efficacy endpoint was evaluated via a pain score from the Ocular Comfort Grading Assessment recorded in a diary.

Patients also graded their symptoms at each office visit, which included photophobia, the chief symptomatic complaint of cataract surgery.

Xibrom(TM) (bromfenac ophthalmic solution)

Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain following cataract surgery. Xibrom, under a different trade name but identical formulation, was launched in Japan in 2000 by Senju Pharmaceuticals Co. Ltd. ISTA acquired U.S. marketing rights for Xibrom in 2002 and launched the
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
6. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
9. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Co-development Terms & Agreements in Pharma, Biotech ... The Co-development Terms and Agreements ... comprehensive understanding and unprecedented access to the ... the worlds leading life science companies. ...
(Date:8/27/2014)... and MENLO PARK, Calif. , Aug. ... DMPI), developer of advanced cancer therapeutics , will ... Annual Rodman & Renshaw Global Investment Conference, sponsored by ... take place Tuesday, September 9th at 2:55 p.m. EDT ... New York Palace Hotel in New York ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Pulse Oximeter Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The pulse oximeter market analysis is provided ...
Breaking Medicine Technology:Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Pulse Oximeter Industry Report 2014 2
... PITTSBURGH, Nov. 10, 2011 Building on the success ... Positive Airway Pressure) mask, Circadiance is proud to introduce ... users will hardly know it,s there. Used ... Feather Weight Tube from Circadiance complements the CPAP mask ...
... VILLAGE, Colo., Nov. 10, 2011 Ampio Pharmaceuticals, ... the "Company"), a company that discovers and develops ... molecular entities ("NMEs"), today announced that an IRB ... for Allergy and Asthma in Denver, Colorado indicates ...
Cached Medicine Technology:Circadiance Launches Revolutionary New CPAP Tube 2Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation 2Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation 3
(Date:8/27/2014)... Delta, a reliable supplier of high quality ... D7R Dozers to its used bulldozer collection. ... that all these items are offered with deep discounts. ... Delta’s market share in the coming September. , ... offer; he has much confidence in the discounted Used ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked Holganix as No. ... exclusive ranking of the nation’s fastest-growing privately held companies. ... most important segment of the economy - America’s independent ... members of the Inc. 500 list include Dell, LinkedIn, ... world’s greatest companies have had their start on the ...
(Date:8/27/2014)... Diego, CA (PRWEB) August 27, 2014 ... insurance policies will now be easier for the public ... insurance prices that are promoted in all 50 states ... . , The different insurers that are generating ... made it possible for adults to use the programmed ...
(Date:8/27/2014)... August 27, 2014 Today, Zane Benefits, ... on compliance tips for administering a premium reimbursement plan. ... in full effect, compliance is top of mind for ... to individual health insurance and premium reimbursement, there are ... In the 35 minute webinar, Zane Benefits President, Rick ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Top 10 Best ... compared many Linux hosting suppliers and announced iPage, Bluehost and ... USA, UK, Canada, Australia and Europe to buy useful hosting ... the most reliable suppliers, iPage has been serving ... years’ development, it has grown into a leader in the ...
Breaking Medicine News(10 mins):Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Well-known SEO Hosts Review Site Top10BestSEOHosting.com Recommends iPage, Bluehost and GoDaddy To Webmasters 2
... topical compound is as effective at treating the skin ... the standard therapy, a less-available, costlier compound injected into ... team from Johns Hopkins University , Harvard ... by Reza F. Ghohestani, M.D., Ph.D., director of the ...
... Receives EU and US Approvals for Intravenous Formulation of ... Sachet PresentationKENILWORTH, N.J., March 5 Schering-Plough Corporation (NYSE: ... Commission and the US FDA both approved the intravenous ... already approved oral form of the drug. Temozolomide ...
... to ExpertsBETHESDA, Md., March 5 The American College of ... the March issue of The American Journal of Gastroenterology. ... update of those published by ACG in 2000. Key ... , ...
... acquisition of NMHC drives GAAP earnings per share growth, ... up from $6.5 million in Q4, ... Corp. ("SXC" or the "Company") (NASDAQ: SXCI , TSX: ... ended December 31, 2008. Financial references are in U.S. dollars unless ...
... Anti-Doping Agency (WADA) has banned athletes from using bottled ... of the sports that it governs.LAKE FOREST, Calif., March ... Anti-Doping Agency (WADA), bottled or canned oxygen is banned ... "Artificially enhancing the uptake, transport or delivery of oxygen ...
... imaging and file conversion services available through Lifeboat,s reseller network; ... , ... Northglenn, CO (PRWEB) March ... the imaging industry, today announced a distribution agreement with Lifeboat ...
Cached Medicine News:Health News:The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 2Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 3Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 2Health News:SXC Health solutions announces strong fourth quarter and year end financial results 3Health News:SXC Health solutions announces strong fourth quarter and year end financial results 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 6Health News:SXC Health solutions announces strong fourth quarter and year end financial results 7Health News:SXC Health solutions announces strong fourth quarter and year end financial results 8Health News:SXC Health solutions announces strong fourth quarter and year end financial results 9Health News:SXC Health solutions announces strong fourth quarter and year end financial results 10Health News:SXC Health solutions announces strong fourth quarter and year end financial results 11Health News:SXC Health solutions announces strong fourth quarter and year end financial results 12Health News:SXC Health solutions announces strong fourth quarter and year end financial results 13Health News:SXC Health solutions announces strong fourth quarter and year end financial results 14Health News:SXC Health solutions announces strong fourth quarter and year end financial results 15Health News:SXC Health solutions announces strong fourth quarter and year end financial results 16Health News:SXC Health solutions announces strong fourth quarter and year end financial results 17Health News:SXC Health solutions announces strong fourth quarter and year end financial results 18Health News:SXC Health solutions announces strong fourth quarter and year end financial results 19Health News:SXC Health solutions announces strong fourth quarter and year end financial results 20Health News:Oxygen4Energy: International Sports News - World Anti-Doping Agency (WADA) Bans Oxygen Use 2Health News:Lifeboat Distribution and ImageDoc USA Sign Distribution Agreement 2
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
... The IMMULITE 1000 immunoassay system ... use, reliability, robust hardware and excellent ... onboard reagents and accommodates onboard dilutions, ... , , Worldwide, IMMULITE 1000 (and ...
Medicine Products: